Back to Search Start Over

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

Authors :
Abdulla, Salim
Salim, Nahya
Machera, Francisca
Kamata, Richard
Juma, Omar
Shomari, Mwanajaa
Kubhoja, Sulende
Mohammed, Ali
Mwangoka, Grace
Aebi, Thomas
Mshinda, Hassan
Schellenberg, David
Carter, Terrell
Villafana, Tonya
Dubois, Marie-Claude
Leach, Amanda J.
Lievens, Marc
Vekemans, Johan
Cohen, Joe
Ballou, W. Ripley
et al.
Abdulla, Salim
Salim, Nahya
Machera, Francisca
Kamata, Richard
Juma, Omar
Shomari, Mwanajaa
Kubhoja, Sulende
Mohammed, Ali
Mwangoka, Grace
Aebi, Thomas
Mshinda, Hassan
Schellenberg, David
Carter, Terrell
Villafana, Tonya
Dubois, Marie-Claude
Leach, Amanda J.
Lievens, Marc
Vekemans, Johan
Cohen, Joe
Ballou, W. Ripley
et al.
Publication Year :
2013

Abstract

BackgroundThe RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization. Safety, immunogenicity and efficacy of the RTS,S/AS02D vaccine candidate when integrated into a standard EPI schedule for infants have been reported over a nine-month surveillance period. This paper describes results following 20 months of follow up. MethodsThis Phase IIb, single-centre, randomized controlled trial enrolled 340 infants in Tanzania to receive three doses of RTS,S/AS02D or hepatitis B vaccine at 8, 12, and 16 weeks of age. All infants also received DTPw/Hib (diphtheria and tetanus toxoids, whole-cell pertussis vaccine, conjugated Haemophilus influenzae type b vaccine) at the same timepoints. The study was double-blinded to month 9 and single-blinded from months 9 to 20. ResultsFrom month 0 to 20, at least one SAE was reported in 57/170 infants who received RTS,S/AS02D (33.5%; 95% confidence interval [CI]: 26.5, 41.2) and 62/170 infants who received hepatitis B vaccine (36.5%; 95% CI: 29.2, 44.2). The SAE profile was similar in both vaccine groups; none were considered to be related to vaccination. At month 20, 18 months after completion of vaccination, 71.8% of recipients of RTS,S/AS02D and 3.8% of recipients of hepatitis B vaccine had seropositive titres for anti-CS antibodies; seroprotective levels of anti-HBs antibodies remained in 100% of recipients of RTS,S/AS02D and 97.7% recipients of hepatitis B vaccine. Anti-HBs antibody GMTs were higher in the RTS,S/AS02D group at all post-vaccination time points compared to control. According to protocol population, vaccine efficacy against multiple episodes of malaria disease was 50.7% (95% CI: -6.5 to 77.1, p = 0.072) and 26.7% (95% CI: -33.1 to 59.6, p = 0.307) over 12 and 18 months post vaccination, respectively. In the Intention to Treat population

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn906436140
Document Type :
Electronic Resource